Survival 79 Percent for Congenital Diaphragmatic Hernia

This article originally appeared here.
Share this content:
Survival 79 Percent for Congenital Diaphragmatic Hernia
Survival 79 Percent for Congenital Diaphragmatic Hernia

WEDNESDAY, Feb. 22, 2017 (HealthDay News) -- Survival is 79 percent for neonates with congenital diaphragmatic hernia (CDH) undergoing surgical repair, with higher survival for those not needing extracorporeal membrane oxygenation (ECMO), according to a study published online Feb. 17 in Pediatric Anesthesia.

Katarina Bojanic, M.D., from the University Hospital Merkur in Zagreb, Croatia, and colleagues performed a retrospective cohort study involving consecutive neonates treated for CDH from 2001 to 2015. Hospital and post-discharge data were reviewed for neonatal, disease, and treatment characteristics for 38 neonates admitted during the study period.

Life support was withdrawn for three neonates who were in extremis. The researchers found that the other 35 neonates underwent surgical repair and eight received ECMO. The overall survival was 79 percent; survival was 89 percent among those who had surgical correction but did not need ECMO, and 75 percent for those who received ECMO and had surgery. Lower hospital survival was seen for liver-up versus liver-down CDH (61 versus 95 percent; odds ratio, 0.08). The median duration of hospitalization was 31 days among survivors. The most noted comorbid conditions after discharge were major chronic pulmonary and gastrointestinal disorders, failure to thrive, and neurodevelopmental delays; these were all more prevalent among neonates requiring ECMO.

"The overall survival of neonates with CDH was 79 percent," the authors write. "A substantial number of survivors, especially those who required ECMO, experienced chronic conditions after discharge."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »